Skip to content
Search

Latest Stories

CCA calls for Pharmacy First expansion to boost antibiotic stewardship and patient care

Pharmacy First data indicates that pharmacists are responsible providers of
gettyimages

Pharmacy First data indicates that pharmacists are responsible providers of antibiotics and they are closely following AMR guidelines

The Company Chemists’ Association (CCA) has urged NHS England to expand the Pharmacy First service by increasing treatment options, adding more conditions, and integrating Independent Prescribing into the service.

This would further promote pharmacists as antimicrobial stewards while enhancing patient access to urgent care, it said.


Managing patient demand for antibiotics remains a challenge for healthcare professionals, including pharmacists.

However, a new report by CCA confirms that pharmacists are acting as responsible providers of antibiotics, in line with Antimicrobial Resistance (AMR) guidelines.

The service allows pharmacies to provide advice and treatment, including prescription-only medication, for seven common conditions: earache, uncomplicated urinary tract infections (UTIs) in women, sore throat, sinusitis, infected insect bites, impetigo, and shingles.

Patients can access the service via GP referrals or by visiting or contacting a pharmacy directly.

The CCA’s analysis of over 150,000 anonymised consultation records from more than 3,000 pharmacies (August-September 2024) revealed that 66 per cent of patients treated for one of the six bacterial conditions received antibiotics (shingles, a viral infection, was excluded).

Around 94 per cent of patients received a complete episode of care without requiring onward referral.

The analysis found that pharmacists were adhering strictly to treatment guidelines, with 88 per cent of antibiotics supplied being first-line treatments, excluding bladder infections where only one treatment option is available through the service.

Additionally, the report showed that when multiple treatment options exist, less than half of patients receive oral antibiotics.

The report noted that adding more treatment options to the service would provide more options to pharmacists and support appropriate antibiotic supply.

To further enhance antibiotic stewardship and expand patient care, the CCA recommends adding more conditions to the Pharmacy First service, such as lower back pain, respiratory tract infections, conjunctivitis, and skin conditions like acne, eczema, and psoriasis.

The CCA also advocates for integrating pharmacist prescribing into the Pharmacy First service, which would “increase the reach and impact, and also further support pharmacists in providing treatment in line with AMS best practice.”

Additionally, it calls for commissioning pharmacies to capture information on patients who do not meet “gateway” criteria.

“This information would enable better understanding of the rate of antibiotics provision through Pharmacy First, as well the workload associated with the service,” the CCA stated.

The service has dramatically increased access to urgent care, particularly in deprived communities, where access to healthcare (including GP appointments) is typically lower.

Between January and September 2024, the Pharmacy First service facilitated over 1.4 million patient appointments that were redirected from general practice via clinical pathway consultations, according to the report.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less